Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 212

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

Open access
Albrecht, Brian K., Gehling, Victor S., Hewitt, Michael C., Vaswani, Rishi G., Côté, Alexandre, Leblanc, Yves, Nasveschuk, Christopher G., Bellon, Steve, Bergeron, Louise, Campbell, Robert, Cantone, Nico, Cooper, Michael R., Cummings, Richard T., Jayaram, Hariharan, Joshi, Shivangi, Mertz, Jennifer A., Neiss, Adrianne, Normant, Emmanuel, O’Meara, Michael, Pardo, Eneida, Poy, Florence, Sandy, Peter, Supko, Jeffrey, Sims, Robert J., Harmange, Jean-Christophe, Taylor, Alexander M., Audia, James E. · 2016 · Journal of Medicinal Chemistry

Abstract

In recent years, inhibition of the interaction between the bromodomain and extra-terminal domain (BET) family of chromatin adaptors and acetyl-lysine residues on chromatin has emerged as a promising approach to regulate the expression of important disease-relevant genes, including MYC, BCL-2, and NF-κB. Here we describe the identification and characterization of a potent and selective benzoisoxazoloazepine BET bromodomain inhibitor that attenuates BET-dependent gene expression in vivo, demonstrates antitumor efficacy in an MV-4-11 mouse xenograft model, and is currently undergoing human clinical trials for hematological malignancies (CPI-0610).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.5b01882

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 212

Metadata

Authors
Albrecht, B. K., Gehling, V. S., Hewitt, M. C., Vaswani, R. G., Côté, A., Leblanc, Y., Nasveschuk, C. G., Bellon, S., Bergeron, L., Campbell, R., Cantone, N., Cooper, M. R., Cummings, R. T., Jayaram, H., Joshi, S., Mertz, J. A., Neiss, A., Normant, E., O’Meara, M., Pardo, E., Poy, F., Sandy, P., Supko, J., Sims, R. J., Harmange, J.-C., Taylor, A. M., & Audia, J. E.
Venue
Journal of Medicinal Chemistry
Published
2016-02-04
Volume
59
Issue
4
Pages
1330-1339
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2270241120
Cited by
212
References
3
FWCI
10.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials. https://app.cochat.ai/papers/10.1021/acs.jmedchem.5b01882
The paper
Albrecht, B. K., Gehling, V. S., Hewitt, M. C., Vaswani, R. G., Côté, A., Leblanc, Y., Nasveschuk, C. G., Bellon, S., Bergeron, L., Campbell, R., Cantone, N., Cooper, M. R., Cummings, R. T., Jayaram, H., Joshi, S., Mertz, J. A., Neiss, A., Normant, E., O’Meara, M., . . . Audia, J. E. (2016). Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5b01882

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.